title: Epigenetic regulation of miR-212 expression in lung cancer.
abstract: Many studies have shown that microRNA expression in cancer may be regulated by epigenetic events. Recently, we found that in lung cancer miR-212 was strongly down-regulated. However, mechanisms involved in the regulation of miR-212 expression are unknown. Therefore, we addressed this point by investigating the molecular mechanisms of miR-212 silencing in lung cancer. We identified histone modifications rather than DNA hypermethylation as epigenetic events that regulate miR-212 levels in NSCLC. Moreover, we found that miR-212 silencing in vivo is closely associated with the severity of the disease.
authors: Fondazione IRCCS SDN, Naples, Italy.
authors: Mariarosaria
authors: M
authors: Incoronato
authors: Loredana
authors: L
authors: Urso
authors: Ana
authors: A
authors: Portela
authors: Mikko O
authors: MO
authors: Laukkanen
authors: Ylermi
authors: Y
authors: Soini
authors: Cristina
authors: C
authors: Quintavalle
authors: Simona
authors: S
authors: Keller
authors: Manel
authors: M
authors: Esteller
authors: Gerolama
authors: G
authors: Condorelli
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D018899:CpG Islands / Q000187:drug effects / Q000235:genetics; D019175:DNA Methylation / Q000187:drug effects / Q000235:genetics; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors; D000071221:Enhancer of Zeste Homolog 2 Protein; D044127:Epigenesis, Genetic / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D020868:Gene Silencing; D006649:Histocompatibility Antigens; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006655:Histone Deacetylases / Q000378:metabolism; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors; D006657:Histones / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D063151:Polycomb Repressive Complex 2; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics; D014157:Transcription Factors / Q000037:antagonists & inhibitors; D024363:Transcription Initiation Site / Q000187:drug effects
chemical_list: D004268:DNA-Binding Proteins; D006649:Histocompatibility Antigens; D056572:Histone Deacetylase Inhibitors; D006657:Histones; C551411:MIRN212 microRNA, human; D035683:MicroRNAs; D014157:Transcription Factors; C445405:EHMT2 protein, human; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D011495:Histone-Lysine N-Methyltransferase; D063151:Polycomb Repressive Complex 2; D006655:Histone Deacetylases